Teva Announces Changes to Executive Management Team
21 July 2021 - 10:00PM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced changes to its leadership team. Brendan O’Grady,
Executive Vice President, North America Commercial, will leave Teva
to pursue a career opportunity outside of the pharmaceutical
industry, and Sven Dethlefs, who currently serves as Teva’s
Executive Vice President, Global Marketing and Portfolio and
International Markets Commercial has been appointed the new head of
North America Commercial.
In addition, Teva announced the following changes to the
Executive Management team:
- Mark Sabag, who currently serves as Chief Human Resources
Officer and head of Global Communications, Brand and ESG, has been
appointed as Executive Vice President, International Markets
Commercial
- Galia Inbar will be promoted to Executive Vice President, Chief
Human Resources Officer, and Global Communications, Brand and
ESG
- Eli Shani will be promoted to Executive Vice President, Global
Marketing and Portfolio
All changes will be effective August 15, 2021.
“On behalf of the Teva Board of Directors and our executive
management team, I want to thank Brendan for his many contributions
to Teva during his 30 years with the company. Most recently, for
his leadership in helping to stabilize the US business and setting
Teva up for future growth as head of North America Commercial,
during challenging times,” said Mr. Kare Schultz, President and
Chief Executive Officer, “I am pleased to announce the appointment
of Sven Dethlefs to this critical role. Sven has been part of the
Executive Management team since 2017 and held leadership roles in
Teva's global specialty business, commercial European business, and
in our global operations. I have every confidence that Sven will
bring great strength to the regional business and the benefit of
patients.”
"I am also proud to announce additional changes to our
leadership team, which include the transition of Mark Sabag to lead
the commercial business in our International Markets, and the
appointment of Galia Inbar and Eli Shani to lead our Human
Resources, Global Communications, Brand and ESG, and our Global
Marketing and Portfolio, respectively. These appointments
demonstrate the quality and depth of our leadership bench, and I
look forward to working closely with Sven, Mark, Galia, Eli, and
the rest of the team as we continue to lead Teva to meet its
targets, implement its strategy and fulfill its mission."
Biographies:
Sven Dethlefs, PhD has been part of the Executive
Management team since 2017 and has held numerous leadership roles
of increasing responsibility in Teva's global specialty business,
commercial European business, and in our global operations. Sven
has played an integral role in optimizing Teva's vast global
portfolio, in the R&D pipeline strategy, and leading global
marketing teams including responsibility for AJOVY®, AUSTEDO® and
Digital Health. Previously, he held positions as global head of
respiratory medicines and chief operating officer of our global
manufacturing operations group, Teva Global Operations (TGO). Sven
became Executive Vice President, Global Marketing & Portfolio
in 2017 and assumed responsibility for international markets
commercial in 2021. Sven joined Teva as general manager, Germany,
in 2008. Prior to joining Teva, he served for over eleven years as
a partner at McKinsey & Company. Sven received his Ph.D. in
biochemistry from the FU Berlin/Pasteur Institute Paris.
Mark Sabag became Executive Vice President, Global Human
Resources in 2013, and then EVP, Chief Human Resources Officer and
Global Communications, Brand and ESG in 2019. Before that, he held
several senior Human Resources positions including Global Deputy
Vice President, Human Resources from 2012 to 2013, Vice President,
Human Resources for Teva’s International Group and Vice President,
Global Human Capital & M&As from 2006 to 2012. Prior to
joining Teva, Mark held several senior global Human Resources roles
at Intel Corporation. Mark holds a B.A. in economics and business
management from Haifa University.
Galia Inbar joined Teva in 2019 with more than 20 years
of human resource and operational experience, and currently holds
the position of Senior Vice President, Global People Operations,
where she leads globally all Teva HR operations. Prior to joining
Teva, Galia held several senior global Human Resources roles at
Amdocs for more than 7 years. Galia holds a BSc in Industrial
Engineering from Tel-Aviv University.
Eli Shani is the current of head of Teva's Global
Business Development and Alliance Management group. He joined Teva
in 2006 as a Vice President in the Corporate Business Development
group where he led acquisitions and divestments. In 2011, he
transitioned to the role of Chief Operating Officer in a joint
venture formed by Teva and P&G focusing on both companies'
global OTC businesses. Prior to joining Teva, Eli was a CFO at an
ophthalmic medical device start-up company, and prior to that an
investment banker working for Credit Suisse and CIBC. He holds a
joint degree in law and accounting from the University of Tel Aviv
and an MBA from the University of Chicago.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and served
by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such
differences include risks relating to uncertainties relating to the
potential benefits and success of our announced senior management
changes and other factors discussed in our Annual Report on Form
10-K for the year ended December 31, 2020, including in the
sections captioned "Risk Factors” and “Forward Looking Statements”
and in our subsequent Quarterly Reports on Form 10-Q.
Forward-looking statements speak only as of the date on which they
are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise.
You are cautioned not to put undue reliance on these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210721005440/en/
IR Contacts
United States Kevin C. Mannix (215) 591-8912 Yael Ashman
972 (3) 914-8262
PR Contacts
United States Kelley Dougherty (973) 832-2810
Israel Yonatan Beker 972 (54) 888 5898
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2024 to Mar 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2023 to Mar 2024